Dance Pharma Inc., Hikma Pharmaceuticals deal

Hikma received exclusive rights to market Dance Pharma's Dance 01 in the Middle East and Africa to treat diabetes. Dance Pharma plans to start Phase III development of the inhaled insulin product nex...